Net loss narrowed year-over-year as PharmaLundensis advanced Phal-501 to clinical readiness and prepared a 9.1 MSEK rights issue to fund trials and commercialization, while CleanTech projects attracted international interest.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.